Annual EBIT
$575.23 M
+$208.14 M+56.70%
December 31, 2024
Summary
- As of February 26, 2025, HALO annual earnings before interest & taxes is $575.23 million, with the most recent change of +$208.14 million (+56.70%) on December 31, 2024.
- During the last 3 years, HALO annual EBIT has risen by +$319.18 million (+124.66%).
- HALO annual EBIT is now at all-time high.
Performance
HALO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
$182.75 M
+$13.08 M+7.71%
December 31, 2024
Summary
- As of February 26, 2025, HALO quarterly earnings before interest & taxes is $182.75 million, with the most recent change of +$13.08 million (+7.71%) on December 31, 2024.
- Over the past year, HALO quarterly EBIT has increased by +$76.36 million (+71.77%).
- HALO quarterly EBIT is now at all-time high.
Performance
HALO Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$575.23 M
+$76.36 M+15.31%
December 31, 2024
Summary
- As of February 26, 2025, HALO TTM earnings before interest & taxes is $575.23 million, with the most recent change of +$76.36 million (+15.31%) on December 31, 2024.
- Over the past year, HALO TTM EBIT has increased by +$208.14 million (+56.70%).
- HALO TTM EBIT is now at all-time high.
Performance
HALO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
HALO EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +56.7% | +71.8% | +56.7% |
| 3 y3 years | +124.7% | +72.0% | +71.2% |
| 5 y5 years | +1048.8% | +72.0% | +71.2% |
HALO EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +124.7% | at high | +451.9% | at high | +137.7% |
| 5 y | 5-year | at high | +1048.8% | at high | +694.7% | at high | +966.4% |
| alltime | all time | at high | +802.5% | at high | +694.7% | at high | +693.6% |
Halozyme Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $575.23 M(+56.7%) | $182.75 M(+7.7%) | $575.23 M(+15.3%) |
| Sep 2024 | - | $169.67 M(+38.8%) | $498.87 M(+14.6%) |
| Jun 2024 | - | $122.27 M(+21.6%) | $435.46 M(+6.0%) |
| Mar 2024 | - | $100.53 M(-5.5%) | $410.85 M(+11.9%) |
| Dec 2023 | $367.09 M(+38.1%) | $106.39 M(+0.1%) | $367.09 M(+9.2%) |
| Sep 2023 | - | $106.27 M(+8.8%) | $336.06 M(+8.1%) |
| Jun 2023 | - | $97.65 M(+72.0%) | $311.01 M(+26.2%) |
| Mar 2023 | - | $56.78 M(-24.7%) | $246.48 M(-7.3%) |
| Dec 2022 | $265.87 M(+3.8%) | $75.36 M(-7.2%) | $265.87 M(+7.5%) |
| Sep 2022 | - | $81.22 M(+145.3%) | $247.37 M(+2.2%) |
| Jun 2022 | - | $33.12 M(-56.5%) | $242.01 M(-19.9%) |
| Mar 2022 | - | $76.17 M(+33.9%) | $302.16 M(+18.0%) |
| Dec 2021 | $256.04 M(+71.1%) | $56.87 M(-25.0%) | $256.04 M(-7.7%) |
| Sep 2021 | - | $75.86 M(-18.7%) | $277.46 M(+14.2%) |
| Jun 2021 | - | $93.27 M(+210.4%) | $242.86 M(+34.6%) |
| Mar 2021 | - | $30.05 M(-61.6%) | $180.47 M(+20.6%) |
| Dec 2020 | $149.68 M(-346.9%) | $78.28 M(+89.7%) | $149.68 M(+268.1%) |
| Sep 2020 | - | $41.26 M(+33.6%) | $40.67 M(-272.9%) |
| Jun 2020 | - | $30.88 M(-4250.4%) | -$23.52 M(-64.6%) |
| Mar 2020 | - | -$744.00 K(-97.6%) | -$66.39 M(+9.5%) |
| Dec 2019 | -$60.62 M(-1.8%) | -$30.73 M(+34.0%) | -$60.62 M(+116.9%) |
| Sep 2019 | - | -$22.92 M(+91.1%) | -$27.95 M(-2.2%) |
| Jun 2019 | - | -$11.99 M(-338.8%) | -$28.59 M(-17.6%) |
| Mar 2019 | - | $5.02 M(+158.1%) | -$34.69 M(-43.8%) |
| Dec 2018 | -$61.75 M(-173.9%) | $1.95 M(-108.3%) | -$61.75 M(-197.5%) |
| Sep 2018 | - | -$23.56 M(+30.3%) | $63.31 M(-33.9%) |
| Jun 2018 | - | -$18.09 M(-17.9%) | $95.74 M(+7.8%) |
| Mar 2018 | - | -$22.04 M(-117.4%) | $88.79 M(+6.2%) |
| Dec 2017 | $83.59 M(-202.1%) | $127.01 M(+1332.4%) | $83.59 M(-227.4%) |
| Sep 2017 | - | $8.87 M(-135.4%) | -$65.62 M(-32.3%) |
| Jun 2017 | - | -$25.04 M(-8.1%) | -$96.90 M(+4.0%) |
| Mar 2017 | - | -$27.24 M(+22.6%) | -$93.18 M(+13.8%) |
| Dec 2016 | -$81.88 M(+202.9%) | -$22.21 M(-0.9%) | -$81.88 M(+51.5%) |
| Sep 2016 | - | -$22.41 M(+5.1%) | -$54.05 M(-1.4%) |
| Jun 2016 | - | -$21.33 M(+33.8%) | -$54.80 M(+87.9%) |
| Mar 2016 | - | -$15.94 M(-383.6%) | -$29.16 M(+7.9%) |
| Dec 2015 | -$27.03 M(-57.0%) | $5.62 M(-124.3%) | -$27.03 M(-26.0%) |
| Sep 2015 | - | -$23.16 M(-636.3%) | -$36.55 M(+13.2%) |
| Jun 2015 | - | $4.32 M(-131.3%) | -$32.29 M(-37.2%) |
| Mar 2015 | - | -$13.81 M(+254.4%) | -$51.43 M(-18.1%) |
| Dec 2014 | -$62.79 M(-21.7%) | -$3.90 M(-79.4%) | -$62.79 M(-21.7%) |
| Sep 2014 | - | -$18.90 M(+27.5%) | -$80.16 M(+0.6%) |
| Jun 2014 | - | -$14.82 M(-41.1%) | -$79.70 M(-8.3%) |
| Mar 2014 | - | -$25.17 M(+18.4%) | -$86.94 M(+8.4%) |
| Dec 2013 | -$80.20 M | -$21.26 M(+15.3%) | -$80.20 M(+26.6%) |
| Sep 2013 | - | -$18.44 M(-16.4%) | -$63.35 M(-2.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$22.06 M(+19.6%) | -$64.91 M(+14.1%) |
| Mar 2013 | - | -$18.44 M(+318.5%) | -$56.87 M(+6.2%) |
| Dec 2012 | -$53.55 M(+170.9%) | -$4.41 M(-78.0%) | -$53.55 M(-20.7%) |
| Sep 2012 | - | -$20.01 M(+42.7%) | -$67.51 M(+59.4%) |
| Jun 2012 | - | -$14.02 M(-7.3%) | -$42.35 M(+67.8%) |
| Mar 2012 | - | -$15.12 M(-17.6%) | -$25.23 M(+27.6%) |
| Dec 2011 | -$19.77 M(-63.6%) | -$18.36 M(-456.3%) | -$19.77 M(+2.5%) |
| Sep 2011 | - | $5.15 M(+66.4%) | -$19.29 M(-47.7%) |
| Jun 2011 | - | $3.10 M(-132.0%) | -$36.88 M(-29.3%) |
| Mar 2011 | - | -$9.66 M(-46.0%) | -$52.13 M(-3.9%) |
| Dec 2010 | -$54.26 M(-7.2%) | -$17.88 M(+43.8%) | -$54.26 M(+10.6%) |
| Sep 2010 | - | -$12.43 M(+2.3%) | -$49.05 M(-3.0%) |
| Jun 2010 | - | -$12.15 M(+3.1%) | -$50.56 M(-8.9%) |
| Mar 2010 | - | -$11.79 M(-7.0%) | -$55.49 M(-5.1%) |
| Dec 2009 | -$58.46 M(+15.9%) | -$12.68 M(-9.1%) | -$58.46 M(-6.9%) |
| Sep 2009 | - | -$13.94 M(-18.4%) | -$62.81 M(+4.6%) |
| Jun 2009 | - | -$17.08 M(+15.8%) | -$60.07 M(+10.5%) |
| Mar 2009 | - | -$14.76 M(-13.3%) | -$54.36 M(+7.8%) |
| Dec 2008 | -$50.43 M(+79.2%) | -$17.03 M(+52.0%) | -$50.43 M(+16.4%) |
| Sep 2008 | - | -$11.20 M(-1.5%) | -$43.34 M(+7.1%) |
| Jun 2008 | - | -$11.37 M(+5.0%) | -$40.45 M(+15.9%) |
| Mar 2008 | - | -$10.83 M(+9.1%) | -$34.90 M(+24.0%) |
| Dec 2007 | -$28.15 M(+80.6%) | -$9.93 M(+19.5%) | -$28.15 M(+23.0%) |
| Sep 2007 | - | -$8.31 M(+42.5%) | -$22.89 M(+24.4%) |
| Jun 2007 | - | -$5.83 M(+42.9%) | -$18.41 M(+15.1%) |
| Mar 2007 | - | -$4.08 M(-12.6%) | -$15.99 M(+2.6%) |
| Dec 2006 | -$15.58 M(+14.9%) | -$4.67 M(+22.0%) | -$15.58 M(+7.5%) |
| Sep 2006 | - | -$3.83 M(+12.0%) | -$14.49 M(+0.4%) |
| Jun 2006 | - | -$3.42 M(-7.0%) | -$14.43 M(+3.4%) |
| Mar 2006 | - | -$3.67 M(+2.6%) | -$13.96 M(+3.0%) |
| Dec 2005 | -$13.56 M(+49.2%) | -$3.58 M(-5.0%) | -$13.56 M(+8.4%) |
| Sep 2005 | - | -$3.77 M(+27.8%) | -$12.51 M(+4.2%) |
| Jun 2005 | - | -$2.95 M(-9.9%) | -$12.01 M(+7.7%) |
| Mar 2005 | - | -$3.27 M(+29.4%) | -$11.15 M(+22.7%) |
| Dec 2004 | -$9.09 M(<-9900.0%) | -$2.53 M(-22.5%) | -$9.09 M(+64.4%) |
| Sep 2004 | - | -$3.26 M(+56.2%) | -$5.53 M(+106.8%) |
| Jun 2004 | - | -$2.09 M(+73.0%) | -$2.67 M(+179.5%) |
| Mar 2004 | - | -$1.21 M(-217.0%) | -$956.20 K(<-9900.0%) |
| Dec 2003 | $0.00(0.0%) | $1.03 M(-352.9%) | $0.00(-100.0%) |
| Sep 2003 | - | -$408.20 K(+9.5%) | -$1.01 M(+64.0%) |
| Jun 2003 | - | -$372.90 K(+48.3%) | -$618.40 K(+134.4%) |
| Mar 2003 | - | -$251.40 K(-1458.9%) | -$263.80 K(<-9900.0%) |
| Dec 2002 | $0.00(-100.0%) | $18.50 K(-246.8%) | $0.00(-100.0%) |
| Sep 2002 | - | -$12.60 K(-31.1%) | -$18.50 K(+213.6%) |
| Jun 2002 | - | -$18.30 K(-247.6%) | -$5900.00(-147.6%) |
| Mar 2002 | - | $12.40 K | $12.40 K |
| Dec 2001 | -$39.70 K | - | - |
FAQ
- What is Halozyme Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual EBIT year-on-year change?
- What is Halozyme Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly EBIT year-on-year change?
- What is Halozyme Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM EBIT year-on-year change?
What is Halozyme Therapeutics annual earnings before interest & taxes?
The current annual EBIT of HALO is $575.23 M
What is the all time high annual EBIT for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual earnings before interest & taxes is $575.23 M
What is Halozyme Therapeutics annual EBIT year-on-year change?
Over the past year, HALO annual earnings before interest & taxes has changed by +$208.14 M (+56.70%)
What is Halozyme Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of HALO is $182.75 M
What is the all time high quarterly EBIT for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly earnings before interest & taxes is $182.75 M
What is Halozyme Therapeutics quarterly EBIT year-on-year change?
Over the past year, HALO quarterly earnings before interest & taxes has changed by +$76.36 M (+71.77%)
What is Halozyme Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of HALO is $575.23 M
What is the all time high TTM EBIT for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM earnings before interest & taxes is $575.23 M
What is Halozyme Therapeutics TTM EBIT year-on-year change?
Over the past year, HALO TTM earnings before interest & taxes has changed by +$208.14 M (+56.70%)